ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO2183

Immunoglobulin G (IgG) Glycosylation, Renal Function, and Antibody-Mediated Rejection in Renal Transplant

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical

Authors

  • Barrios, Clara, Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain
  • Redondo-Pachón, Dolores, Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain
  • Perez saez, Maria jose, Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain
  • Sierra Ochoa, Adriana, Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain
  • Arias, Carlos Enrique, Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain
  • Burballa, Carla, Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain
  • Buxeda, Anna, Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain
  • Pascual, Julio, Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain
  • Crespo, Marta, Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain
Background

IgG glycome composition is a key regulator of immune system modulating inflammation at multiple levels. It has been associated to aging, infections response, autoimmune diseases or early kidney failure. Its role in KT has not been studied. Our aim was to analyze the prognostic and diagnostic value of IgG_glycans in renal function after 1year of KT and in antibody-mediated rejection (AMR)

Methods

We analyzed 24 essential IgG glycans by Highperformance LiquidChromatography grouped them by biological function, according to the proportion of Galactosylated, Agalactosylated, Sialicylated, Fucosylated and Bisecting-GlcNAc structures. We measured baseline IgG_glycans and one year after KT in 248 recipients (62%M:38%M) of 55.9±13.6 years, 36 with AMR. Association models were adjusted by donor characteristics, baseline renal function, age/sex, BMI, ATN-postKT and comorbidities

Results

Differences between IgG_glycans at baseline and 1year values were associated with the achieved renal function: Higher Sialization (Coeff [95% CI] 2.07 [0.23-0.3.9]) and Galactosylation (1.84 [0.0-3.6]), the better renal function and higher proportion of agalactosylated glycans associated worse renal function -2.02 [-4.1- -0.34]. AMR occurred more frequently in patients with a higher proportion of Agalactosylated glycans (OR [95% CI]) 1.7 [1.15-2.51] and less in those with a greater proportion of Galactosylates 0.59 [0.4-0.87], Sialicylates 0.67 [0.45-0.9] and Bisecting-GlcNAc 0.66 [0-45-0.99] (Figure)

Conclusion

Glycans, that modulate the IgG function, are a potential prognostic tool for renal function in KT and as a diagnostic support in the identification of patients who develop AMR